SCHEMBL24418646

SCHEMBL24418646

Cc1cccc(F)c1-n1nc2c(-c3ccc(N4CCN(CCO)CC4)nc3)n[nH]c2cc1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TLR9 Q9NR96 1/20 0.41
TLR8 Q9NR97 1/20 0.41
TLR7 Q9NYK1 1/20 0.41
PIM1 P11309 3/20 0.40
TNKS O95271 1/20 0.38
NTRK1 P04629 2/20 0.37
DYRK1A Q13627 2/20 0.37
DYRK3 O43781 1/20 0.37
CCNT1 O60563 1/20 0.37
CDK9 P50750 1/20 0.37
DYRK2 Q92630 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
PLK4 O00444 2/20 0.37
FLT3 P36888 2/20 0.37
AURKA O14965 3/20 0.36
LRRK2 Q5S007 2/20 0.36
WNT3A P56704 1/20 0.36
GAA P10253 1/20 0.36
AURKB Q96GD4 1/20 0.36
ACVR1 Q04771 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26351325 0.92 AURKA (0.44) TLR9TLR8TLR7PIM1TNKS
SCHEMBL24418437 0.91 NTRK1 (0.40) PIM1TNKSNTRK1PLK4FLT3
SCHEMBL29606913 0.91 TNKS (0.46) TNKSDYRK1APLK4FLT3AURKA
SCHEMBL24418315 0.91 TNKS (0.46) TNKSDYRK1APLK4FLT3AURKA
SCHEMBL24418647 0.91 FGFR2 (0.38) TLR7PIM1TNKSNTRK1DYRK1A
SCHEMBL24418379 0.88 WNT3A (0.42) TLR8TLR7PIM1TNKSNTRK1
SCHEMBL26501879 0.88 NTRK1 (0.37) PIM1TNKSNTRK1PLK4FLT3
SCHEMBL24418445 0.88 LRRK2 (0.38) PIM1TNKSNTRK1PLK4FLT3
SCHEMBL24418798 0.87 FGFR2 (0.40) PIM1NTRK1DYRK1APLK4FLT3
SCHEMBL24418443 0.86 JAK2 (0.38) TNKSNTRK1PLK4FLT3AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4223759-B1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO LTD (CN) 2025-06-11 EP claimed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US claimed
EP-4223759-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Broadenbio Co., Ltd. (CN) 2023-08-09 EP claimed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US disclosed
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF BROADENBIO CO., LTD. (CN) 2023-10-12 US disclosed
EP-4223759-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Broadenbio Co., Ltd. (CN) 2023-08-09 EP disclosed
WO-2022095904-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 北京伯汇生物技术有限公司 2022-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230322789-A1 PYRAZOLOPYRIDAZINONE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF PDXK, CMPK1, GCK TLR9 4725/4885TLR8 4581/4885TLR7 4379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.